It is unclear how important CRISPR-Cas systems are for protecting natural populations of bacteria against infections by mobile genetic elements by Westra, ER & Levin, BR
PERSPECTIVE
It is unclear how important CRISPR-Cas systems
are for protecting natural populations of bacteria
against infections by mobile genetic elements
Edze R. Westraa,1,2 and Bruce R. Levinb,1,2
Edited by Paul E. Turner, Yale University, New Haven, CT, and approved September 11, 2020 (received for review February 7, 2020)
Articles on CRISPR commonly open with some variant of the phrase “these short palindromic repeats and
their associated endonucleases (Cas) are an adaptive immune system that exists to protect bacteria and
archaea from viruses and infections with other mobile genetic elements.” There is an abundance of ge-
nomic data consistent with the hypothesis that CRISPR plays this role in natural populations of bacteria and
archaea, and experimental demonstrations with a few species of bacteria and their phage and plasmids
show that CRISPR-Cas systems can play this role in vitro. Not at all clear are the ubiquity, magnitude, and
nature of the contribution of CRISPR-Cas systems to the ecology and evolution of natural populations of
microbes and the strength of selection mediated by different types of phage and plasmids to the evolution
and maintenance of CRISPR-Cas systems. In this perspective, with the aid of heuristic mathematical–
computer simulation models, we explore the a priori conditions under which exposure to lytic and tem-
perate phage and conjugative plasmids will select for and maintain CRISPR-Cas systems in populations of
bacteria and archaea. We review the existing literature addressing these ecological and evolutionary
questions and highlight the experimental and other evidence needed to fully understand the conditions
responsible for the evolution and maintenance of CRISPR-Cas systems and the contribution of these sys-
tems to the ecology and evolution of bacteria, archaea, and the mobile genetic elements that infect them.
CRISPR-Cas | bacteria | phage | evolution
In 1987, a study by Ishino and colleagues (1) aimed at
analyzing the nucleotide sequence of the iap
(isozyme-converting alkaline phosphatase) gene in
Escherichia coli serendipitously led to the first-ever
description of a CRISPR array. Specifically, they iden-
tified 14 repetitive sequences of 29 base pairs (bp)
each at the 3′ end of the iap gene that were inter-
spersed by 32- to 33-bp variable sequences (1, 2).
Over the next years, identification of CRISPR arrays
in other gram-negative bacteria, gram-positives, and
in Archaea (3–7) triggered a quest to identify their bi-
ological function (reviewed in ref. 8). Meanwhile, as
more whole-genome sequences became available
and CRISPR detection algorithms were developed, it
became clear that these arrays of repeating sequences
are common in prokaryotes, with estimated frequencies
of ∼30 to 40% in Bacteria and 90% in the Archaea
(9–13), with clear variation between phyla (14). An im-
portant step in understanding the function of CRISPRs
was the identification of so-called cas genes (for CRISPR
associated) that are often found in the neighborhood of
CRISPR arrays (15). Bioinformatics analyses expanded
the known repertoire of cas genes (11, 16–19), shed
light on their evolutionary origins (20, 21), and led to
a comprehensive classification of cas gene combina-
tions into two classes and an increasing number of
types and subtypes of CRISPR-Cas systems that differ
in key mechanistic aspects (12).
The original idea that CRISPR-Cas is an adaptive
immune system came from observations that se-
quences in CRISPR arrays on the chromosomes of bac-
teria match those of phage and other foreign genetic
aEnvironment and Sustainability Institute, Biosciences, University of Exeter, Penryn, TR10 9FE Cornwall, United Kingdom; and bDepartment of
Biology, Emory University, Atlanta, GA 30307
Author contributions: B.R.L. carried out the mathematical modeling; and E.R.W. and B.R.L. wrote the paper.
The authors declare no competing interest.
This article is a PNAS Direct Submission.
This open access article is distributed under Creative Commons Attribution License 4.0 (CC BY).
1E.W. and B.L. contributed equally to this work.
2To whom correspondence may be addressed. Email: westra.edze@gmail.com or blevin@emory.edu.
This article contains supporting information online at https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1915966117/-/DCSupplemental.
First published October 29, 2020.









































elements (10, 22, 23). Cas genes were—based on their domains
and predicted catalytic activities—suggested to encode the pro-
tein machinery that carries out the various steps of the immune
response (11). The first experimental evidence in support of this
hypothesis came from a joint effort by industrial and academic
partners, who showed that the lactic acid bacterium Streptococ-
cus thermophilus acquired postinfection resistance (hereafter im-
munity) against viral infection by inserting sequences from the
viral genome into CRISPR loci on the bacterial genome (24).
Viruses in turn were found to overcome CRISPR-based immunity
by mutation of the target sequence on their genome (25). To-
gether, these findings fueled models of how bacteria with CRISPR
systems and their viruses might coevolve (26–28). In parallel with
this experimental work, genomic data suggested that CRISPR loci
evolve rapidly in natural populations of acidophilic bacteria (29)
and that the DNA sequences between these palindromic repeats,
spacers, were homologous to that of phage, plasmids, and
transposons (30).
Since these pioneering studies, spacer uptake from phages
and other mobile genetic elements (MGEs) in bacteria and
archaea from natural and human-associated environments has
been inferred from variation in spacer sequences within and be-
tween populations of the same species and from their homology
to MGE genomes (31–40). Experimental observations of spacer
uptake in the laboratory in response to plasmid and phage infec-
tion have been made among others in engineered E. coli strains
(41–43) and Staphylococcus aureus (44–47) and in wild-type Pec-
tobacterium atrosepticum (48), Pseudomonas aeruginosa (49, 50),
Roseburia intestinalis (51), Sulfolobus solfataricus (52), Streptococ-
cus mutans (37), and other species (reviewed in ref. 53). Consistent
with the hypothesis that CRISPR-Cas protects bacteria from infec-
tions, some MGEs encode so-called anti-CRISPR genes that block
the activity of the immune system (reviewed in ref. 54).
How Important Is CRISPR to the Ecology and Evolution of
Bacteria and Archaea?
While the preceding evidence and arguments demonstrate that
CRISPR-Cas can protect bacteria and archaea from infectious
DNAs, it is not at all clear how commonly CRISPR plays this role in
natural populations of these microbes. If CRISPR commonly pro-
tects bacteria from infectious DNAs, one might expect a strong
negative correlation between the presence of a CRISPR system
and the signatures of horizontal gene transfer in the same ge-
nomes. For restriction-modification systems—the most prevalent
innate immune system of bacteria and archaea—such correlations
can be readily detected (55). Yet, in the case of CRISPR-Cas the
evidence is ambiguous, with some studies suggesting that
CRISPR does form a barrier for the movement of mobile genes
betweenmicrobial species (56, 57), whereas other studies arrive at
the opposite conclusion (58–60). Furthermore, most spacers from
sequenced isolates have no homology to viral or plasmid se-
quences in databases (40), and the same holds for spacers
extracted from metagenomes (39).
If indeed CRISPR-Cas is commonly important for protecting
populations of microbes from phage and preventing the acqui-
sition of MGEs, there should be no trouble detecting (in the lab-
oratory or in nature) CRISPR-Cas–encoding bacteria and archaea
that acquire spacers from novel sources of infectious DNAs to
become immune to those infections. However, other than the
bacterial species listed above, there are very few wild-type bac-
teria or archaea for which spacer acquisition from phage or plas-
mids has been demonstrated to occur at observable frequencies.
Moreover, even for species that have been reported to acquire
spacers, it is not clear whether they do so in response to only few
or many phages and plasmids. Because in most bacteria and ar-
chaea, spacer acquisition is rare, a range of elegant methods has
been developed to detect these events (44, 61–66), and while this
has propelled our understanding of the mechanisms of spacer
acquisition (53) and CRISPR-mediated immunity (67), it raises
questions concerning the ecological importance of CRISPR-Cas
immune systems. Perhaps this is because many of the domesti-
cated bacteria and archaea that we use for research simply lost
their ability to rapidly acquire spacers. Could it be that the quest
to find culturable bacteria, archaea, phage, and plasmids with
these properties has not be adequately extensive? Or could it be
that the results of these quests are commonly negative and
therefore, not reported? Sequence data analysis also provides a
mixed picture: CRISPR loci in some species appear to evolve
rapidly (e.g., refs. 29, 30, and 32 and reviewed in ref. 68), whereas
others are relatively static over long periods (60, 69).
Open Questions
We hope the preceding has convinced the reader that the fol-
lowing are open questions: (i ) how commonly CRISPR-Cas sys-
tems protect populations of bacteria and archaea from infections
with deleterious MGEs and (ii) the corollary, that extant CRISPR-
Cas systems are maintained by selection mediated by these in-
fectious genetic elements. To address these issues, we explore
the answers to the following four questions.
i) Under what conditions will immunity be selected for in pop-
ulations with functional CRISPR-Cas systems (CRISPR+ bacte-
ria and archaea) confronted with phage and plasmids?
ii) Under what conditions will bacteria and archaea with func-
tional CRISPR-Cas immune systems be able to invade popu-
lations that lack CRISPR-Cas systems (CRISPR)?
iii) What is the contribution of CRISPR immunity to the population
dynamics, ecology, and evolution of prokaryotes and
their MGEs?
iv) What are the characteristics of MGEs that lead to spacer ac-
quisition by bacteria during an infection?
We explore the first three of these questions in two ways: 1)
with heuristic mathematical–computer simulation models of the
dynamics of microbes and infectious genetic elements, and 2)
with a review of the experimental and other empirical studies that
provide some answers to these questions. We separately consider
the three main sources of infectious DNAs: lytic phage, temperate
phage, and conjugative plasmids. For each of these, we consider
the invasion conditions: the conditions under which selection
mediated by these infectious MGEs will lead to 1) the ascent of
immune cells in populations with functional CRISPR-Cas systems,
CRISPR+, and 2) the establishment of CRISPR-Cas, CRISPR+, in
populations that do not have a functional CRISPR-Cas system,
CRISPR−. The equations for the models used and those employed
for the analysis of their properties are presented in SI Appendix, as
are the caveats and concerns about the limitations of these
models and our analyses of their properties.
Lytic Phage.
What the models and theory tell us.We use a simple model that
captures the molecular mechanism of types I and II CRISPR-Cas
systems, which are the most abundant systems [30 and 8% of
genomes, respectively (70)]. In this model, there is a single pop-
ulation of lytic phage, V; a population of bacteria that lacks a































functional CRISPR-Cas system, and a population that carries a
functional CRISPR-Cas system (CRISPR− and CRISPR+, respec-
tively). The CRISPR− bacteria are of two possible states, phage
sensitive S and phage resistant SR, due to phage receptor mu-
tations. The CRISPR+ bacteria can be of three states: phage sen-
sitive not immune (C), phage resistant (CR) due to phage receptor
mutations, and phage immune (CI) due to the acquisition of a
phage-targeting spacer in the CRISPR array (SI Appendix, Fig. S1).
We assume that resistant bacteria, SR and CR, are refractory to the
phage; the phage does not adsorb to these cells. By contrast,
immune bacteria, CI, can be infected by the phage, but phages
do not replicate and are lost. Resistance is acquired by random
mutation and immunity through the acquisition of a spacer by
infection with the phage. Both acquisition of a resistance mutation
and the acquisition of spacers are stochastic processes, which we
model with a Monte Carlo protocol.
First, we consider the conditions under which resistance, CR,
and CRISPR-Cas–mediated immunity, CI, will invade a CRISPR+
phage-sensitive population, C, at equilibrium with the phage. If
the CRISPR+ population, C, is unable to generate resistant mu-
tants, CR, but can acquire spacers and the likelihood of acquiring
a spacer upon infection with the phage is on the order of 10−8 or
greater, there are broad conditions under which CRISPR-Cas will
be selected for and immune cells, CI, will become established in a
CRISPR+ population. This can be seen from the change in the
mean densities of immune cells in Fig. 1A. If both immunity and
resistance can be generated, both will become established
(Fig. 1A). Examples of the associated population dynamics are in
SI Appendix, Fig. S2 A–C. In the simulations presented in Fig. 1A,
upon first encounter with the phage, immunity and resistance are
equally likely to be generated, and therefore, resistant and im-
mune cells are equally likely to ascend to dominate the CRISPR+
population (we assume no costs of resistance). If immunity is
10-fold more likely to be generated than resistance, immune cells
are more likely to dominate the population (SI Appendix, Fig.
S2D).
The conditions for bacteria with CRISPR-Cas (CRISPR+) to be-
come established in a CRISPR− population of sensitive bacteria at
equilibrium with a lytic phage are more restrictive than those for
CRISPR-Cas–mediated immunity to become established in a
population of CRISPR+ bacteria. When the frequency of the in-
vading population of CRISPR+ cells is low, 10−4 or less, the
CRISPR+ population does not become established (Fig. 1B).
Moreover, in only 2 of the 200 runs did the CRISPR+ population
invade when the initial frequency of CRISPR+ was 10−3. The rea-
son for the difficulty of CRISPR+ bacteria to become established in
CRISPR− populations when bacteria with this immune system are
initially rare is that, when confronted with phage, resistant mutants
are likely to be generated in the dominant population of CRISPR−
-sensitive cells (SI Appendix, Fig. S3 A–C). The conditions for the
invasion of CRISPR+ in a CRISPR− population are greater if the rate
of spacer acquisition is higher or if the CRISPR− population is
unable to generate resistant mutants (SI Appendix, Fig. S3 D
and E)
The invasion theory considered above addresses only one el-
ement of the role of phage in the evolution of CRISPR-Cas. The
other element is the length of time selection mediated by lytic
phage will favor CRISPR-Cas immune systems. This will depend on
1) the capacity of the phage to generate protospacer mutants, 2)
the capacity of the bacteria to acquire novel spacers to counter
protospacer mutations in the phage, 3) the rates at which these
novel spacers are acquired, 4) the rate of mutation to resistance,
and 5) the fitness costs associated with the carriage of CRISPR-
Cas, surface resistance, and protospacer mutations in the phage.
Some theoretical studies have partly addressed this issue (27, 28,
71), but the models employed do not consider how all five of the
above-listed factors contribute to the length of time selection for
CRISPR-Cas will be maintained.
What the experiments and genomic data say. While we are
unaware of experimental studies that examine the invasion of
CRISPR+ into established CRISPR− populations of bacteria or ar-
chaea, there have been several experimental studies of the
population and evolutionary dynamics of lytic phage and bacteria
with CRISPR-Cas systems. As anticipated by the models, CRISPR-
Cas immunity readily evolves in S. thermophilus strains exposed
to virulent phage (24, 72). In this system, bacteria with envelope
resistance are normally not detected, and an extended spacer–
protospacer arms race can ensue when these bacteria and phage
coexist in serial transfer culture (24, 73–75). While the phage will
eventually be lost, the duration of the arms race and the diversity
of spacers and phage protospacer mutants that evolve during this
process can be substantial. In these experimental populations, the
densities of bacteria remain at levels similar to those of phage-free
A B
Fig. 1. Lytic phage-mediated selection for CRISPR-Cas–mediated immunity and envelope resistance. Invasion conditions. (A) Monte Carlo
simulations of selection for CRISPR-Cas immunity and resistance in a CRISPR+ phage-sensitive population initially at equilibrium with the phage.
Mean and SE of the changes in density of CRISPR+ immune and resistant bacteria across 100 runs. Green bars are for a population of CRISPR+
bacteria that cannot generate resistant mutants. Red and blue bars are for populations that can evolve both CRISPR-Cas immunity (red bars) and
envelope resistance (blue bars) with equal probabilities. (B) Invasion of CRISPR+ into a population of CRISPR−-sensitive bacteria at equilibrium
with phage, with different initial frequencies of CRISPR+ (blue= 0.1, orange= 0.01, green= 0.001, red= 0.0001). Resistant and immune bacteria
can be generated in the invading CRISPR+ population, and resistance can be generated in the initially dominant CRISPR− population. Mean and
SE of the frequency of CRISPR+ bacteria over time across 200 runs. Parameters: vC = vCI = vCR = 0.7, δ = 10−7, β = 50, e = 5 × 10−7, k = 1, RR =
500, w = 0.1, r(0) = 500, μSR = 10−8, μRS = 10−8, x = 1.667 × 10−8, and the total volume of the vessel is Vol = 100 mL The initial densities of
bacteria and phage in these simulations are at the equilibrium for a phage-limited population: C* = 2 × 104 and V* = 6 × 106, respectively.































populations. Stated another way, the bacterial populations are
limited by resources, rather than the phage.
In these experiments, it is clear that the coevolutionary dy-
namics observed for S. thermophilus and its phage can be at-
tributed to CRISPR-Cas–mediated immunity to the phage.
Resistant bacteria only evolve if the CRISPR-Cas system is inacti-
vated by either antisense RNA expression (76) or an anti-CRISPR
(acr) gene encoded by the phage (77), with resistance due to
mutations in either the receptor or intracellular host genes re-
quired for completing the phage life cycle. This system, therefore,
corresponds well with the theoretical scenario in Fig. 1A (green
bars), which therefore may explain why the evolution of CRISPR
immunity is so commonly observed in this model organism.
Also consistent with the theoretical predictions are the results
of experiments with bacteria that can evolve both CRISPR im-
munity by the acquisition of spacers and resistance by mutation of
the phage receptors. For example, P. aeruginosa strain PA14 ei-
ther evolves resistance against phage DMS3vir (a temperate
phage locked in the lytic cycle) by mutation of the type IV pilus or
immunity by the acquisition of spacers into its CRISPR arrays (49,
50). Experimental manipulation of the bacterial mutation rate
shows that which of these two defense mechanisms prevails
during short-term infection studies strongly depends on the rate
at which receptor mutants are generated in the population (78).
Similarly, the rates of spacer acquisition matter: bacteria with
“primed” CRISPR-Cas systems acquire spacers at a higher rate
compared with bacteria with naïve CRISPR-Cas systems; this
translates in a strong increase in the proportion of bacteria that
evolved CRISPR-Cas immunity following phage exposure (41, 42,
48, 61, 79–82). This phenomenon was observed first for many type
I where it relies on an imperfect match between a preexisting
spacer and the infectious genome (ref. 53 has mechanistic details),
and more recently, a similar mechanism was also observed for
type II CRISPR-Cas systems (47, 79). When bacteria are exposed to
defective phage or when bacteria carry both a restriction modifi-
cation and a CRISPR-Cas system, the rates of spacer acquisition
are also elevated, and again, this leads to higher levels of evolved
CRISPR immunity in short-term experiments (83, 84). The typically
low frequencies of CRISPR immunity that many bacteria evolve in
the laboratory may therefore be at least in part explained by the
high mutation rates and large population sizes relative to the rates
of spacer acquisition in many model systems, although the fitness
costs and benefits of CRISPR-based immunity and surface-based
resistance will also be important (50, 85), especially in the long
term, which has been reviewed elsewhere (86).
Temperate Phage.
What the models and theory tell us. In our model (depicted in SI
Appendix, Fig. S4), there is a single population of free temperate
phage, P, and five populations of bacteria. Bacteria that lack a
functional CRISPR-Cas system, CRISPR−, can exist in two states:
susceptible nonlysogens, S, and lysogens, L. Bacteria that carry a
functional CRISPR-Cas system, CRISPR+, can exist in three states:
sensitive nonlysogens, C; lysogens, CL; or CRISPR immune, CI.
Infections occur at random at a rate proportional to the product of
the densities of free temperate phage, P, and the bacteria. Ly-
sogens and CRISPR immune bacteria can be infected by free
phage, but the phage does not replicate and is removed from the
free phage population. Upon infection of CRISPR−-sensitive cells,
S, a fraction λ (0 ≤ λ ≤1) produces lysogens, L. The remaining (1 −
λ) infections result in lysis of the host to generate free phage
(i.e., the lytic cycle) (87). Infections of CRISPR+-sensitive cells, C,
have three possible outcomes: a fraction λ (0 ≤ λ ≤ 1 − x) produces
lysogens, CL with the remaining (1 − x − λ) producing lytic in-
fections, and killing the infected host. By the acquisition of a
spacer from the phage, a fraction x (0 ≤ x ≤ 1) of the infections
produces CRISPR-Cas immune cells, CI. In addition, at a rate y (0 ≤
y ≤1), CRISPR-Cas immune cells are generated by lysogens,
through the acquisition of a spacer from the prophage. For this
analysis, we are not considering lytic mutants of the temperate
phage or envelope-resistant mutants.
In Fig. 2 and SI Appendix, Fig. S5, we consider the conditions
in which selection mediated by temperate phage will lead to the
establishment of CRISPR-Cas immunity in a CRISPR+ population
and the establishment of bacteria with CRISPR-Cas (CRISPR+) in a
CRISPR− population. During the early stages of infection, tem-
perate phages mostly transmit horizontally through the lytic cycle,
and selection for CRISPR immunity will therefore initially be similar
to that observed for the lytic phage (Fig. 1 and SI Appendix, Fig.
S5A). Following this, a large subpopulation of lysogens will form
that coexists with bacteria that acquired CRISPR immunity in re-
sponse to horizontally transmitting phage (88). To explore the
long-term selection pressures for CRISPR immunity and invasion
of CRISPR+ into CRISPR− populations, we start our simulations
B
A
Fig. 2. Selection mediated by temperate phage. (A) The
establishment of CRISPR immunity in a population of CRISPR+
bacteria at equilibrium with a temperate phage. Changes in the
density of CRISPR-Cas immune bacteria are depicted [colony forming
units per milliliter (cfu*ml−1)]. (B) The invasion of CRISPR+ bacteria
into a population of CRISPR− bacteria at equilibriumwith a temperate
phage. Changes in the densities of CRISPR+ bacteria are depicted.
Carrying the prophage is associated with a 14% advantage, a 10%
cost, a 25% cost, or no cost, as indicated. The parameter values are SI
Appendix, Fig. S5 C and F.































when the bacterial populations are at equilibrium with the tem-
perate phage and therefore, dominated by lysogens (SI Appen-
dix, Fig. S5B). Under those conditions, for selection mediated by
temperate phage to lead to the establishment of CRISPR-Cas
immune cells in populations with functional CRISPR-Cas sys-
tems, either lysogens have to generate immune cells or the pro-
phage has to reduce the fitness of lysogens relative to
nonlysogens (Fig. 2A). The rate of ascent of the immune cells is
inversely proportional to the fitness of the lysogens. For selection
mediated by temperate phage to lead to the invasion of CRISPR+
bacteria in a CRISPR− population, the fitness of lysogens needs to
be less than or equal to that of nonlysogens. If the carriage of the
prophage augments the fitness of the bacteria, as may be the case
(89, 90), CRISPR immune bacteria will be selected against, and the
CRISPR+ population will not be able to invade a population
without this immune system (Fig. 2B) (88).
What the experiments and data say. There is evidence that
CRISPR-Cas systems target temperate phage in nature. For ex-
ample, spacers encoded by P. aeruginosa isolates with type I
CRISPR-Cas systems from cystic fibrosis lungs were found to fre-
quently target related groups of temperate phages (including
DMS3). Surprisingly, however, in these patients, no spacer ac-
quisition was observed over time (60). By contrast, in an experi-
mental study where a wound model was infected with a mix of six
P. aeruginosa strains, CRISPR immunity was found to evolve in P.
aeruginosa strain PA14 against a prophage carried by one of the
strains, known as strain B23-2 (91). Another recent study with P.
aeruginosa PA14 and its phage DMS3 showed that carrying a
primed CRISPR-Cas immune system is, in fact, maladaptive during
temperate phage infection, due to immunopathology in CRISPR+
lysogens since the partial matching spacer triggers cleavage of
the prophage. The associated fitness costs caused a rapid inva-
sion of spontaneous mutants that had lost their CRISPR-Cas im-
mune system (88). Acquisition of perfectly matching spacers in
lysogens amplified these fitness costs since this programs the
immune system to attack the prophage inside the bacterial ge-
nome even more strongly. Such self-targeting by CRISPR-Cas is
well known to be highly toxic (92–99), even for type III CRISPR-Cas
systems that target only transcriptionally active DNA (100, 101).
Finally, a recent and exciting study showed that R. intestinalis in
the mouse gut can evolve high levels of CRISPR-based immunity
when one of its active prophages evolves to become hyperviru-
lent (i.e., virulent phage mutants that can infect the lysogen) (51).
This, however, brings us to what is anticipated for lytic phage. We
are unaware of empirical studies that have explored the contri-
bution of temperate phage to the establishment of CRISPR-Cas in
CRISPR− populations.
Conjugative Plasmids.
What the models and theory tell us. In our model of the pop-
ulation dynamics of CRISPR-Cas immunity and conjugative plas-
mids, there are five populations of bacteria (SI Appendix, Fig. S6).
Two lack a functional CRISPR-Cas system, are CRISPR−, and can
exist in two states: one carrying the plasmid and one not (DP and S,
respectively). Three populations carry a functional CRISPR-Cas
system, CRISPR+, and exist in three states: plasmid free, C; plas-
mid bearing, CP; and one that is plasmid free but immune to the
acquisition of the plasmid, CI. Plasmid transfer is by conjugation,
which occurs via random contact between plasmid-bearing and
plasmid-free cells (102). A “mating” between DP or CP and S
produces SP. A fraction x (0 ≤ x ≤ 1) of mating between DP or CP
with C produces CP, and the remaining fraction of the mating (1 −
x) produces cells that remain plasmid free but have acquired
CRISPR immunity, CI. These CRISPR-Cas immune cells do not take
up the plasmid.
The population dynamics of temperate phage and conjugative
plasmids are different (87, 102) (compare the temperate phage
dynamics in SI Appendix, Fig. S5 A and D with the plasmid dy-
namics in SI Appendix, Fig. S7 A and D). On the other hand, the
conditions under which these infectiously transmitted genetic el-
ements will favor the invasion of CRISPR-Cas immune bacteria into
CRISPR+ populations and CRISPR+ bacteria into CRISPR− pop-
ulations are virtually identical (SI Appendix, Fig. S7 C and F). The
reason for this is that simulations are initiated at equilibrium where
cells carrying the MGEs are the dominant population. Whether
CRISPR-Cas immune cells will invade and become established in
populations with lysogens and bacteria carrying conjugative
plasmids depends on the fitness cost of these genetic elements:
the greater the cost, the broader the conditions for the estab-
lishment and maintenance of these elements. As with temperate
phage, if the plasmid increases the fitness of the bacteria, CRISPR-
Cas immunity would be selected against (103).
What the experiments and data say. Experimental studies
demonstrate that bacteria can evolve CRISPR-based immunity
against plasmids, and in the case of type I CRISPR-Cas systems,
spacer acquisition is accelerated if the CRISPR immune system is
primed. Most commonly, this priming is accomplished by engi-
neering the plasmid in a way that it contains a sequence with a
partial match to a preexisting spacer on the genome of a CRISPR+
host (41, 48, 61, 104). As anticipated by the model, CRISPR im-
munity will be selected against if the plasmid provides a net
benefit to the host: for example, when it confers resistance to an
antibiotic that is present in the environment. Rare mutants that
lack an intact CRISPR-Cas immune system will quickly replace the
dominant CRISPR+ population (105). The model predicts that if
the carriage of the plasmid engenders a fitness cost, CRISPR-
mediated immunity to that plasmid will be favored. To our
knowledge, this has not been demonstrated experimentally. In-
deed, the evidence we are aware of is inconsistent with this hy-
pothesis. A study with engineered E. coli strains showed that even
under these conditions, CRISPR immunity can be maladaptive
because the time between infection and clearance of the plasmid
may allow for the expression of toxin/antitoxin cassettes. This, in
turn, triggers a significant cost of plasmid removal because
(short-lived) antitoxin is no longer produced to neutralize the long-
lived toxin molecules (106). How common this is, however, is not
at all clear. We anticipate that CRISPR immunity will be favored
when the plasmid engenders a fitness cost, provided that any
costs of plasmid removal do not outweigh the benefits of being
plasmid free. We are unaware of any experimental or other em-
pirical studies that have addressed the question of the conditions
under which plasmid-mediated selection will favor the invasion of
bacteria with CRISPR-Cas systems into CRISPR− populations.
Other ReasonsWhy Virulent PhageMay Not Select for CRISPR
Immunity. In the heuristic model considered here and the ex-
periments described in the preceding section, the acquisition of
spacers confers immunity to the MGE from whence the spacers
are derived. This may not always be the case. More and more
MGEs are found to encode anti-CRISPR (acr) genes that suppress
CRISPR-Cas immune systems through a range of different mech-
anisms and with often high specificity for a single subtype
(107–116). The ability of acr genes to bypass immunity of bacteria
that are already CRISPR immune varies (117, 118), but even the































weakest acr genes characterized to date effectively block the
evolution of CRISPR immunity (119).
Other viruses can bypass CRISPR immunity without a need for
acr genes. Some “jumbophages,”which are a class of phages with
genome sizes that exceed 200 kb, have been reported to form
nucleus-like structure during infection (120–122). These structures
contain the phage genomes, which shield them from DNA-
targeting CRISPR-Cas systems but not from systems that have
RNA-targeting activity, such as types III-A and VI-A CRISPR-Cas
(123, 124). This variation in the level of protection explains why in
nature spacer acquisition from nucleus-forming jumbophages is
detected more frequently for bacteria that carry type III systems
compared with those that carry type I-E or I-F systems (123). A lack
of protection by CRISPR immunity is not limited to jumbophages:
E. coli strains carrying type I-E CRISPR-Cas that were engineered
to carry a single targeting spacer against different phages
revealed a lack of protection against phages R1-37 (a giant phage)
and T4 (125). The ability of phage T4 to bypass type I-E CRISPR
immunity is at least in part attributable to their genome containing
glucosyl-5-hydroxymethylcytosine instead of cytosine (126), and
this cytosine modification also confers infectivity to the phage
when bacteria have type II-A CRISPR-based immunity (126, 127)
but not when they have type V-A CRISPR-based immunity (126).
Type I-E CRISPR-Cas offers protection against phage T7 but only
under low phage densities; at high multiplicity of infection, the
cultures were lysed as efficiently as uninduced controls. Efficient
protection against T5 was only observed if the CRISPR spacer
targeted a pre-early gene (125). Furthermore, a recent study
demonstrated that a type I-F CRISPR-Cas system of P. atrosepti-
cum reduced the efficiency of plaquing of two virulent phages
ϕTE and ϕM1 when the immune system was engineered to carry
spacers targeting these phages. Interestingly, CRISPR-Cas was
unable to rescue the host from cell death, hence resulting in an
abortive infection-like phenotype that blocks phage propagation
(128). It remains to be determined if and when CRISPR immunity
would evolve in bacterial populations exposed to these phages.
These observations are in stark contrast with the high levels of
protection against virulent mutants of temperate phage. Exam-
ples include high levels of CRISPR-based immunity observed in P.
aeruginosa strain PA14 against its phage DMS3vir, which we
discussed above. Mild or strong overexpression of the type I-E
CRISPR-Cas system of E. coli targeting the nonlysogenic mutant
λvir provides full immunity, with efficiency of plaquing around 10−
6 (125, 129). Similarly, the type II-A CRISPR-Cas immune system of
Streptococcus pyogenes SF370 provides high levels of immunity
when expressed in S. aureus RN4220 against the staphylococcal
phage ϕNM4γ4, a lytic mutant of ϕNM4 (44–46), and the type III-A
from Staphylococcus epidermidis RP62a provides high levels of
immunity when expressed in S. aureus RN4220 against phage
ϕNM1γ6, a lytic mutant of the temperate phage ϕNM1 (101).
Mapping the variability in the levels of protection conferred by
CRISPR-Cas immunity using a wider range of CRISPR immune
systems and phages will be critical to understand when and where
these systems matter.
Consequences of CRISPR-Cas Immunity to the Population
Dynamics, Ecology, and (Co-)Evolution of Bacteria and
Lytic Phage
In experiments where bacteria evolve high levels of CRISPR-based
immunity, three possible outcomes have been observed: the
phage 1) is being eliminated in short order, 2) persists for an ex-
tended time in spacer–protospacer arms race but is eventually to
be lost, or 3) persists without coevolution. The first outcome is
observed when P. aeruginosa PA14 is infected with DMS3vir (130,
131). This is because these bacteria acquire many different
spacers at the population level, which increases the degree of
protection since it reduces the evolution and spread of phage that
overcome host immunity (88, 130, 132), which they can do by
point mutation (25) or deletion of the target regions on the phage
genome (133). A spacer–protospacer arms race is observed when
the spacer diversity at the population-level is reduced. In this case,
the phage can evolve to overcome host immunity, and hosts, in
turn, need to acquire novel spacers to regain immunity. This co-
evolutionary interaction is observed when S. thermophilus is in-
fected by the lytic phage 2972: bacteria and phage coexist and
coevolve for an extended time eventually for the phage to be lost
(73, 75, 134). Phage extinction is in this system due to the arms
race being asymmetrical: acquisition of novel spacers is cost free
for the host (135), whereas accumulating point mutations reduces
the fitness of the phage (136). Moreover, the host population
gradually increases the diversity of spacers, which makes it harder
for the phage to keep up with the host (75). Finally, the phage may
continue to be maintained without coevolution, when bacteria
with CRISPR immunity in the population continuously acquire
mutations in their CRISPR-Cas immune systems that cause phe-
notypic reversion to sensitivity (74) or when there is a continuous
influx of sensitive bacteria due to immigration (137). While im-
portant progress has been made in understanding the conse-
quences of the evolution of CRISPR immunity, most studies have
been carried out in highly simplified environments with a single
host species infected with a single phage in well-mixed and
nutrient-rich broth. Future studies that examine these interactions
under more ecologically relevant conditions are desperately
needed to understand how CRISPR-Cas systems shape microbial
population and evolutionary dynamics in nature.
Conclusion and Future Directions
We do not question the validity of the hypothesis that CRISPR-Cas
systems can protect bacteria and archaea from infections with
deleterious MGEs. However, what remains unclear is the magni-
tude of the contribution of these systems to the ecology and
evolution of populations of bacteria and archaea and their phage
and other MGEs. As outlined above, many key questions remain.
First, more experimental and observational studies are needed to
understand not only how frequently but also when, where, and
why CRISPR-Cas systems play a role in defense against MGEs
(138). Second, it remains unclear how commonly selection medi-
ated byMGEs is responsible for the existence and maintenance of
CRISPR-Cas systems in populations of bacteria and archaea and
how this is determined by the type of MGE. Third, while CRISPR-
Cas systems clearly spread by horizontal gene transfer, it remains
unclear how these genes are able to invade a population from
rare, especially if the bacteria or archaea can evolve envelope
resistance as well. Finally, our understanding of the ecological and
evolutionary consequences of CRISPR-Cas immune responses is
limited to in vitro experiments that lack much of the biotic and
abiotic complexity of natural environments. Could it be that the
biotic and abiotic complexity of the real world, where communi-
ties of microbes include multiple species and strains as well as
diversity in phage and plasmids, are spatially structured, and exist
in fluctuating environments, is critical to the evolution and main-
tenance of CRISPR (50, 85, 139–141)? Filling these gaps in our
current understanding of CRISPR ecology and evolution requires
interdisciplinary approaches that combine observational studies































and mathematical and computer simulation models, as well as
population and evolutionary dynamics experiments. The question
is how can we do experiments in a way that they would also
provide a test of the generality of the hypotheses that are being
examined. For that, we would need a diverse array of culturable
bacteria and archaea with functional CRISPR-Cas systems and a
diverse set of phage and plasmids, which inevitably require
many different research teams to examine these questions. This
brings us back to our concern about the dearth of bacteria and
archaea phage and plasmid systems amenable for these ex-
perimental studies and the “fishing expedition” dilemma that a
quest to find new systems engenders. However, it is always more
difficult publishing negative evidence, no matter how informa-
tive that evidence would be. We argue that there is a pressing
need to publish any negative results of spacer acquisition in
response to MGEs since knowing which culturable bacteria and
archaea with functional CRISPR-Cas do and do not acquire
spacers and how this depends on the type of infectious DNA will
be critical to fully understand the evolutionary ecology of
CRISPR-Cas.
Data Availability. All study data are included in the article and
SI Appendix.
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